Disc Medicine, Inc. Current Liabilities
Disc Medicine, Inc. (IRON) had Current Liabilities of $30.36 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Liabilities, Current $30.36M.
- 2026-03-31: Liabilities, Current $31.14M.
- 2025-12-31: Liabilities, Current $36.64M.
- 2025-09-30: Liabilities, Current $26.74M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $30.36M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $31.14M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $36.64M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $26.74M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $20.61M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $18.74M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $23.32M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $25.47M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $20.31M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $14.85M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $21.44M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $14.42M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $9.68M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $9.98M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $22.58M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $1.46M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $6.44M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $12.67M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $13.42M 10-K · filed 2023-03-31 | $14.83M 10-K · filed 2022-03-10 |
| 2021-09-30 | $12.66M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $11.51M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $13.78M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $24.88M 10-K · filed 2022-03-10 | $597.57K 10-K · filed 2021-03-29 |
| 2020-09-30 | $552.40K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |